首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Vascular dementia Italian sulodexide study (VA.D.I.S.S.). Clinical and biological results.
【24h】

Vascular dementia Italian sulodexide study (VA.D.I.S.S.). Clinical and biological results.

机译:血管性痴呆意大利sulodexide研究(VA.D.I.S.S.)。临床和生物学结果。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

In order to evaluate the biological effects on some haemostasis factors of antithrombotic-hemorheological treatments on patients with vascular dementia, a multicenter, randomized, double-blind, double-dummy, study comparing sulodexide (Sdx, 50 mg bid orally for 6 months) and pentoxifylline (Ptx, 400 mg tid orally for six months) was carried out. Eighty-six patients, 46 in Sdx group, 40 in Ptx group, fulfilling the NINDS-AIREN criteria for probable vascular dementia were evaluated. Plasma fibrinogen levels showed a significant reduction in both groups, in patients with high basal levels (> or = 350 mg/dl), the reduction being earlier in Sdx group (2nd month of therapy) than in Ptx group (4th month of therapy). In Sdx group a significant reduction in factor VII-Ag (baseline 102.8 U/dl; 6th month 90.1 U/dl) was also observed. Both drugs induced a slight reduction in activated factor VII levels as well. A parallel improvement of G.B.S. Rating Scale for dementia scores was observed in Sdx group. These results seem to indicate that sulodexide treatment can have positive effects in vascular dementia.
机译:为了评估抗血栓性血液流变学治疗对血管性痴呆患者的某些止血因子的生物学效应,进行了多中心,随机,双盲,双虚拟研究,比较了舒洛地肽(Sdx,50 mg口服两次,持续6个月)和进行己酮可可碱(Ptx,口服tid 400 mg,持续六个月)。评估了86例患者,其中Sdx组46例,Ptx组40例,这些患者符合可能的血管性痴呆的NINDS-AIREN标准。在高基础水平(>或= 350 mg / dl)的患者中,两组的血浆纤维蛋白原水平均显着降低,Sdx组(治疗的第二个月)的降低时间早于Ptx组(治疗的第四个月) 。在Sdx组中,还观察到因子VII-Ag显着降低(基线102.8 U / dl;第6个月90.1 U / dl)。两种药物也引起活化因子VII水平的轻微降低。 G.B.S.的并行改进在Sdx组中观察到痴呆评分等级量表。这些结果似乎表明舒洛地昔治疗对血管性痴呆具有积极作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号